Panobinostat
Drug Therapy
Chinese PLA General HospitalSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
2 Active assets in the Drug Therapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUOROURACILUM China Medical University, China | Phase 2 | CCC |
Irinotecan Wang Jiayu | Phase 2 | CCC |
Calcium folinate pentahydrate China Medical University, China | Phase 2 | CCC |
(+)-VINCRISTINE Wang Jiayu | Phase 2 | CCC |
Capecitabine China Medical University, China | Phase 2 | CCC |
Eloxatin China Medical University, China | Phase 2 | CCC |
Same molecule, other indications
Panobinostat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →